Chemokine receptors in advanced breast cancer: differential expression in metastatic disease sites with diagnostic and therapeutic implications

Abstract

These results indicate that CXCR4 can contribute to the homing of breast cancer cells to the bone. This finding might have important clinical implications since patients with metastatic bone disease may achieve the highest benefit from a CXCR4-targeted therapy.

Different Expression Patterns of CXCR4, CCR7, Maspin and FOXP3 in Luminal Breast Cancers and Their Sentinel Node Metastases

“…Other investigators reported similar results with 57-84% CCR7 positivity in their cases (3,27). Interestingly, our luminal B tumors showed significantly more CCR7 positivity than luminal A tumors, which could reflect a more aggressive phenotype.…”

“…Several studies including one meta-analysis have shown CXCR4 expression to correlate with axillary LN metastases (3,5,6,(25)(26)(27). In our study, a high, significant concordance (75%) between CXCR4-positive PTs and their metastases existed.…”

“…Similarly, Liu et al reported 100% concordance between PTs and axillary metastases (3). Interestingly, Cabioglu et al showed CXCR4 positivity most often in tumors with bone metastases (27), suggesting CXCR4 to contribute to homing of breast cancer cells to bone.…”

“…Interestingly, our luminal B tumors showed significantly more CCR7 positivity than luminal A tumors, which could reflect a more aggressive phenotype. CCR7 expression has been correlated to more aggressive tumor features, such as LN metastases (6,27) and decreased survival (3).…”

The oral tyrosine kinase inhibitors lapatinib and sunitinib: new opportunities for the treatment of brain metastases from breast cancer?

“…The highly predictive role of primitive breast cancer erbB2 status versus that of metastatic tissues has been reported [14]. Moreover, erbB2 expression is not a rare finding in breast cancer tissue from BM [15]. On the basis of these considerations, it could be useful to treat erbB2-expressing BM with a drug that targets erbB2 and that is also able to cross the BBB.…”